Type the names Joaquin Duato and Margot Robbie into a search bar and you’ll find an odd pairing. One name belongs to the boardroom. The other belongs to the red carpet. So why do people search for them together?
Here’s the straight answer. No public record links the two. They don’t share a company, a film project, or a family tree. Each has built a remarkable career in a completely different world.
This guide treats them as two separate stories. You’ll get verified career details for each person, a look at how they lead and a clear 2026 update. You’ll also get side-by-side tables that make the contrast easy to see.
Joaquin Duato and Margot Robbie at a Glance
Start with the quick view. This table gives you the basics before we go deeper.
| Detail | Joaquin Duato | Margot Robbie |
|---|---|---|
| Main role | Chairman and CEO of Johnson & Johnson | Actor and film producer |
| Home country | Spain (dual U.S. and Spanish citizen) | Australia |
| Organization | Johnson & Johnson (about 138,000 employees) | LuckyChap Entertainment (co-founder) |
| Current role since | CEO since January 2022 and chairman since January 2023 | Producer since 2014 and a film actor since the early 2010s |
| Industry | Healthcare, pharmaceuticals and medical technology | Film and television |
| Big 2026 moments | Economic Club of Washington interview, PepsiCo board seat | Wuthering Heights release in February |
| How success is measured | Sales, earnings, drug approvals, shareholder returns | Box office, reviews, awards, project pipeline |
The table shows one thing right away. Duato and Robbie work in different industries with different yardsticks. That difference shapes everything else in this article.
Are Joaquin Duato and Margot Robbie Connected?
You came here for an answer. Let’s give it first.
What the public record shows
There’s no documented professional or personal connection between Joaquin Duato and Margot Robbie. Johnson & Johnson’s leadership pages, its SEC filings and the credits of Robbie’s films don’t link them. Neither person has publicly named the other as a colleague, partner or relative.
Here’s what you won’t find:
- A shared business venture
- A film or production credit that ties them together
- A family relationship
- A joint public appearance that suggests a partnership
That’s a short list because there’s nothing to add to it.
Why people search for the two names together
Search engines often pair names for reasons that have nothing to do with the people. Two well-known figures can trend in the same week. A reader might also compare a business leader with an entertainer to understand how different kinds of influence work.
Whatever the reason, the useful move is to read each profile on its own terms. The rest of this article does exactly that.
Joaquin Duato’s Career at Johnson & Johnson
Let’s start with the executive. Joaquin Duato’s story is one of long tenure. He didn’t parachute into the top job. He climbed there over more than three decades.
From Janssen to the executive committee
Duato began his J&J journey in Spain in 1989. He worked inside the company’s pharmaceutical business, known as Janssen. Over the years he held roles across several countries and functions.
The timeline below shows the major steps.
| Period | Role | Why it matters |
|---|---|---|
| 1989 | Joined J&J in Spain | Started a career that now spans over three decades |
| 2009–2011 | Company Group Chairman, Americas, Janssen Pharmaceuticals | Ran pharma operations across the Americas |
| 2011–2018 | Executive Vice President and Worldwide Chairman, Pharmaceuticals | Led J&J’s largest business |
| 2018–2021 | Vice Chair of the Executive Committee | Shaped strategy and technology plans at the top level |
| January 2022 | Chief Executive Officer | Took over from Alex Gorsky |
| January 2023 | Chairman of the Board | Added the chairman title to his CEO role |
Notice the pattern. Each step added scope. He moved from a country team to a regional business, then to a global division and finally to the whole company.
Becoming CEO and chairman
J&J announced the leadership change in August 2021. Alex Gorsky, who had led the company since 2012, stepped aside at the start of 2022. He cited family health reasons. The board called the handover the result of long-term succession planning.
At the time, Duato said he felt honored to serve as the company’s next CEO. That’s a typical line for a CEO announcement. The more telling detail came from Gorsky. He said he’d watched Duato take on complex medical and business problems for about 25 years.
Duato took the chairman role about a year later. Since then he has held both titles.
Education and honors
Duato’s background reflects his international career.
- MBA: ESADE business school in Barcelona
- Master of International Management: Thunderbird School of Global Management in Arizona
- Citizenship: Dual citizen of the United States and Spain
- Honor: In 2023, King Felipe VI of Spain awarded him the Order of Civil Merit, Commander by Number
That award matters for a simple reason. It shows how a Spanish-born executive’s rise at an American company became a point of national pride back home.
How Joaquin Duato Leads: Results and Decisions
A career timeline tells you where someone has been. Decisions tell you how they lead. So let’s look at the choices that define Duato’s tenure.
Case study: the Kenvue separation
Consumer health was once a core piece of J&J. Think of the brands you’d find in a typical bathroom cabinet. Under Duato, the company chose to split that business off.
Here’s how it unfolded:
- 2021: J&J announced plans to separate its consumer health business.
- May 2023: The new company, Kenvue, went public.
- 2023: J&J completed its exit through a share exchange offer.
The result was a more focused J&J. The company now concentrates on two areas: Innovative Medicine (prescription drugs) and MedTech (devices and surgical technology).
Why does this matter? Big companies rarely shrink on purpose. This move traded size for focus. It also set the stage for the dealmaking that followed.
Case study: buying into medical technology and new medicines
Duato has pushed J&J to buy companies in fast-growing areas. The deals below show the pattern.
| Deal | Approximate value | Area | What it added |
|---|---|---|---|
| Abiomed (closed 2022) | $16.6 billion | Heart pumps | A leader in heart recovery devices |
| Shockwave Medical (closed 2024) | $13.1 billion | Vascular care | Technology for treating calcified arteries |
| Ambrx (closed 2024) | About $2 billion | Cancer drugs | Targeted cancer drug technology |
| Intra-Cellular Therapies (closed 2025) | About $14.6 billion | Brain health | Treatments for psychiatric and neurological conditions |
Add those up and you see a strategy. J&J is betting on heart care, cancer and brain health. Those areas pair rising patient needs with strong demand.
What J&J’s board said about 2025
Every year, J&J’s board reviews the CEO’s performance and publishes its findings in a proxy statement. The 2026 filing covers 2025. It gives us hard facts.
The board said the company exceeded its combined financial and strategic goals in 2025. It also said that happened despite the company’s biggest loss-of-exclusivity event in more than a decade. That phrase refers to the point when a blockbuster drug loses patent protection and cheaper copies arrive. For J&J, that drug was Stelara.
The board credited Duato with several priorities:
- Growth: Accelerating existing brands and launching new products
- Portfolio changes: Acquisitions and divestitures to reach higher-growth segments
- R&D: Meeting all priority research milestones
- Financial goals: Beating targets for operational sales, adjusted earnings per share and free cash flow
For scale, J&J reported about $88.8 billion in sales for 2024.
The pay table from the proxy
Executive pay is public for listed companies. That openness is a big difference from the entertainment world, and we’ll come back to it later.
| Pay item (from J&J’s 2026 proxy) | Figure |
|---|---|
| 2025 annual performance bonus | 118.3% of target |
| 2025 long-term incentives | 145% of target |
| 2026 base salary rate | $1,750,000 |
The board raised his base salary rate for 2026 after reviewing market data. Most of an executive’s pay at this level comes from bonuses and stock. Base salary is only a small slice.
A leadership style built on process
Duato’s public record points to a steady, process-driven approach. He rose through a pharma career where trials run for years. Patience and discipline come with that territory.
You can see the same habits in how he handles company structure. He doesn’t chase headlines. He reshapes the portfolio, then reports results against clear targets.
Joaquin Duato in 2026
What has the J&J chief been doing this year? Three developments stand out.
The 140th anniversary and a high-profile interview
J&J turned 140 in 2026. The company dates to 1886. To mark the occasion, the Economic Club of Washington, D.C. hosted a dinner on June 16, 2026. Investor and interviewer David Rubenstein sat down with Duato for a public conversation.
That’s a significant stage. The Economic Club draws leaders from business and government. A CEO invited there is typically a figure the policy world wants to hear from.
A seat on the PepsiCo board
In late September 2026, PepsiCo announced that Duato will join its board as an independent director. The seat starts in December. PepsiCo’s board has 12 members.
Why does this matter? Large companies recruit sitting CEOs for their boards because they bring experience with global operations and regulation. PepsiCo is working to reshape its product lineup and restart growth. A leader who has just reorganized a huge company brings relevant experience.
The company at a glance in 2026
| J&J snapshot | Detail |
|---|---|
| Employees | About 138,000 worldwide |
| Core businesses | Innovative Medicine and MedTech |
| CEO since | January 2022 |
| Chairman since | January 2023 |
| 2026 base salary rate for CEO | $1.75 million |
| Founded | 1886 |
If you’re tracking Joaquin Duato’s leadership in 2026, the story is steady execution. The headlines are anniversaries, board seats and earnings reports. They aren’t scandals or sudden reversals.
Margot Robbie Rise in Film
Now let’s turn to the actor. Margot Robbie’s story is one of fast moves and big bets. She went from regional Australian television to the top of Hollywood in about a decade.
From Neighbours to Hollywood
Robbie was born on July 2, 1990, in Dalby, Queensland. She grew up in southeast Queensland and began acting as a young adult.
Her first big break came on the Australian soap opera Neighbours. She played Donna Freedman from 2008 to 2011. The show gave her steady work and a training ground. Then she moved to the United States.
Her next step was the ABC drama Pan Am (2011–2012). It was short-lived but it put her in front of American audiences. A much bigger opportunity followed.
The breakthrough role
In 2013, Robbie appeared in The Wolf of Wall Street, directed by Martin Scorsese. She played Naomi Lapaglia opposite Leonardo DiCaprio. It was only her first major film role. Yet she held her own in scenes with one of the biggest stars in the world.
That performance did two things. It proved she could handle serious material. It also opened doors to bigger projects.
Margot Robbie’s major film roles
The table below tracks the roles that shaped her career.
| Film | Year | Her role | Why it matters |
|---|---|---|---|
| The Wolf of Wall Street | 2013 | Naomi Lapaglia | Her breakout with Scorsese and DiCaprio |
| Suicide Squad | 2016 | Harley Quinn | Launched a comic-book character she’d play again |
| I, Tonya | 2017 | Tonya Harding | Earned her first Oscar nomination (Best Actress) and a producer credit |
| Mary Queen of Scots | 2018 | Queen Elizabeth I | Showed her range in period drama |
| Bombshell | 2019 | Kayla Pospisil | Earned an Oscar nomination (Best Supporting Actress) |
| Once Upon a Time in Hollywood | 2019 | Sharon Tate | Worked with Quentin Tarantino |
| Birds of Prey | 2020 | Harley Quinn | Her company produced it |
| Barbie | 2023 | Barbie | Became a global box office hit |
| A Big Bold Beautiful Journey | 2025 | Lead role | Sci-fi romance with Colin Farrell |
| Wuthering Heights | 2026 | Catherine Earnshaw | Gothic romance directed by Emerald Fennell |
Look at the choices. Robbie mixes blockbusters with director-driven films. She’ll play a comic-book antihero one year and a real-life figure the next. That mix protects her from being boxed in.
Awards and recognition
Robbie has earned Academy Award nominations in both acting and producing:
- Best Actress for I, Tonya
- Best Supporting Actress for Bombshell
- Best Picture (as producer) for Promising Young Woman
- Best Picture (as producer) for Barbie
That spread is unusual. Most stars get recognized for one side of the business. Robbie has earned notice on both.
Margot Robbie as a Producer
Acting made Robbie famous. Producing gave her power. And that second chapter may matter more in the long run.
LuckyChap Entertainment
In 2014, Robbie co-founded LuckyChap Entertainment with Tom Ackerley, Josey McNamara and Sophia Kerr. Ackerley is also her husband. The idea was simple. She wanted to make stories she believed in instead of waiting for offers.
LuckyChap has built a track record across film and TV. The list below shows the range.
- I, Tonya (2017): The company’s early breakout, which earned Robbie an acting nomination
- Birds of Prey (2020): A studio comic-book film with a female-led ensemble
- Promising Young Woman (2020): Emerald Fennell’s debut feature, which won the Oscar for Best Original Screenplay
- Dollface (2019–2022): A comedy series for Hulu
- Maid (2021): A drama series for Netflix
- Saltburn (2023): Fennell’s second feature
- Barbie (2023): The company’s biggest hit
- Wuthering Heights (2026): Fennell’s third film with LuckyChap
That list covers movies and television. It covers small films and giant ones. The common thread is a distinct creative voice. LuckyChap tends to back directors with a strong point of view.
Case study: Emerald Fennell and LuckyChap
The partnership between LuckyChap and writer-director Emerald Fennell shows how a producer can shape a career.
- Promising Young Woman: A dark revenge thriller. It won Fennell the Oscar for Best Original Screenplay.
- Saltburn: A twisted class drama with a cult following.
- Wuthering Heights: A bold take on Emily Brontë’s 1847 novel. It marks the third collaboration between Fennell and LuckyChap.
Robbie has praised Fennell’s talent for pulling viewers into a story. She once said Fennell “gets in your brain.” That’s a producer talking about a director she trusts.
The lesson is clear. Repeat partnerships build trust. Studios take chances on a team with a record. And creators do better work when they feel supported.
Case study: producing Barbie
Barbie gave Robbie her biggest win as a producer. Greta Gerwig directed the film for Warner Bros. LuckyChap produced it. Robbie also starred in the title role.
The numbers speak for themselves:
- Worldwide box office: More than $1.4 billion
- Rank: The highest-grossing film of 2023
- Awards: Multiple Oscar nominations, including Best Picture (for the producers)
The film worked because it did more than sell a toy. It paired a famous brand with a director who had something to say. Robbie fought to get that mix right. She believed in a risky idea and bet her company on it.
From actor to creative producer
Many actors launch production companies. Few turn them into real studios. Here’s how Robbie’s approach differs.
- She picks directors first. She backs voices, not just titles.
- She stays involved. She often produces and stars in the same film.
- She diversifies. LuckyChap works in film, TV and branded properties.
- She builds a team. Her partners handle daily operations.
That last point matters. A company built around one star can collapse when the star steps back. LuckyChap has a deeper bench.
Margot Robbie in 2026
What’s Robbie up to this year? The big story is Wuthering Heights.
The release of Wuthering Heights
Warner Bros. released the film on February 11, 2026, in the UK and February 13, 2026, in the U.S. That timing put it right on Valentine’s Day weekend.
Here’s what you should know about the film:
- Director and writer: Emerald Fennell
- Based on: Emily Brontë’s 1847 novel
- Robbie’s role: Catherine Earnshaw
- Co-star: Jacob Elordi as Heathcliff
- Supporting cast: Hong Chau, Alison Oliver and Shazad Latif
- Music: Original songs by Charli XCX
- Producers: LuckyChap and MRC
The project fits her pattern. It’s a literary adaptation with a daring director. It pairs a major star with a story people already know. It also gives LuckyChap another chance to prove that director-led films can find big audiences.
What came before it
Robbie also starred in A Big Bold Beautiful Journey in 2025. Kogonada directed the sci-fi romance. Colin Farrell co-starred. The film shows her interest in smaller, more offbeat projects between big releases.
The LuckyChap pipeline
LuckyChap has also announced projects built on well-known brands. The most talked-about include a live-action Monopoly movie and a film based on The Sims. Check each project’s current status before you plan around it. Release timing in Hollywood shifts often.
Here’s the takeaway for 2026. Margot Robbie is working on both sides of the camera. She acts in select roles and keeps a full producing slate.
Corporate Leadership vs. Creative Leadership
Now let’s put the two side by side. Both Joaquin Duato and Margot Robbie lead people. Yet the way they do it couldn’t be more different.
| Question | Joaquin Duato (corporate leadership) | Margot Robbie (creative leadership) |
|---|---|---|
| Who do they answer to? | A board and shareholders | Financiers, studios and creative partners |
| How big is the team? | About 138,000 employees | A small core team plus project crews |
| How long is a project? | Drug programs can run a decade | A film runs one to three years |
| How is success measured? | Earnings, sales, drug approvals | Box office, reviews, awards |
| How public are results? | Quarterly reports and SEC filings | Release dates, ratings and ticket sales |
| Biggest risk | A failed trial or lost patent | A film that flops |
| What they sell | Medicines and medical devices | Stories and experiences |
Let’s unpack a few rows.
Scale and structure
Duato manages a global organization with thousands of managers. Policies, supply chains and regulators all shape his choices. A single decision can touch millions of patients.
Robbie runs a much smaller operation. A handful of partners decide which projects to back. They can move fast. Yet each bet carries personal and financial weight.
Time and risk
A pharmaceutical company thinks in decades. Researchers might work on one molecule for ten years before it reaches patients. That slow rhythm rewards patience.
A film company thinks in seasons. A project can go from script to screen in two years. The audience responds in a single opening weekend. That rhythm rewards sharp instincts.
Two kinds of influence
Duato’s influence flows through resources and regulation. When J&J invests billions in a new treatment area, researchers, hospitals and patients feel it.
Robbie’s influence flows through culture and attention. When Barbie became a hit, it changed how studios thought about female-led films. Neither form of influence is better. They simply work differently.
Public Profiles and Media Attention
How do the media cover each of them? The answer reveals a lot about their worlds.
Duato: filings, interviews and boards
Business leaders earn headlines through numbers and appointments. Duato’s public profile builds on:
- Earnings reports every quarter
- Annual proxy statements that detail pay and performance
- Conference and interview appearances like the June 2026 Economic Club event
- Board appointments like the PepsiCo seat
- Honors like Spain’s Order of Civil Merit
You rarely see him in tabloids. His coverage tends to stay in business and healthcare news. That’s typical for a CEO of a regulated company.
Robbie: premieres, press tours and production news
Robbie’s attention comes from a different machine. Her public profile builds on:
- Film premieres and press tours
- Awards-season coverage
- Fashion and red-carpet moments
- Production announcements from LuckyChap
- Interviews that discuss her roles and choices
Robbie’s Barbie press tour became a cultural event in 2023. Fans followed her outfits and her appearances. Few executives ever see that level of daily interest.
How to read 2026 coverage
Here’s a practical tip. Not every page that mentions these names tells the truth. Some low-quality sites publish thin, contradictory claims. Some say Wuthering Heights is still in pre-production this fall. Warner Bros. already released it in February.
Before you trust a claim, check it against a primary source.
| If you want facts about… | Check this first |
|---|---|
| Duato’s role and pay | J&J’s website and its SEC filings |
| J&J’s results | The company’s quarterly earnings releases |
| Duato’s board seat | PepsiCo’s official announcement |
| Robbie’s film release dates | The studio’s press materials |
| Robbie’s awards | The Academy’s official records |
| LuckyChap’s slate | LuckyChap’s own channels and trade publications |
A few minutes of checking saves you from repeating a bad claim.
What Their Careers Share
We’ve stressed the differences. Still, a few real overlaps exist. Keep in mind that these are broad patterns and not signs of any link between the two.
Long-term international careers
Both Joaquin Duato and Margot Robbie built careers away from where they started. Duato began in Spain and ended up running an American giant. Robbie started in Queensland and ended up producing global films.
Both also built their careers over many years. Duato spent more than three decades inside one company. Robbie has spent about 18 years in screen acting.
Expanding responsibilities
Each one has taken on more than they started with.
- Duato: Country role, then regional chair, then global division head, then CEO, then chairman
- Robbie: Actor, then producer, then company co-founder, then studio partner
The pattern is the same. Neither stayed in a single lane.
Evolving professional identity
Duato once led a pharma division. Now he guides a broader healthcare company and sits on another company’s board. Robbie began as a TV actor. Now she’s a producer with a major slate.
That evolution is the real parallel. Both moved from doing the work to shaping where the work goes.
Where does the comparison end? It ends at the facts. They run different organizations in different industries. Any deeper connection would be guesswork.
Joaquin Duato and Margot Robbie: Two Separate Stories Worth Understanding
Let’s pull the pieces together. Each profile stands on its own.
Joaquin Duato’s professional story
Duato is a builder of institutions. He joined J&J in 1989 and rose through pharma. He became CEO in 2022 and chairman in 2023. He guided the Kenvue separation, backed major acquisitions in heart care, cancer and brain health and led the company through the loss of Stelara’s exclusivity.
His board says the company beat its 2025 goals. He spent 2026 celebrating J&J’s 140th year and preparing to join PepsiCo’s board.
Margot Robbie’s professional story
Robbie is a builder of projects. She went from Neighbours to Scorsese’s set to Oscar nominations. She co-founded LuckyChap in 2014 and helped turn it into a force behind Promising Young Woman, Saltburn and Barbie.
In 2026 she starred in and produced Wuthering Heights and kept growing her company’s slate.
Why their names deserve separate treatment
There are three good reasons to keep them apart.
- Different industries. Healthcare and film follow different rules.
- Different measures of success. One lives by earnings and approvals. The other lives by box office and reviews.
- No documented connection. Linking them would add noise and no value.
When you read about Joaquin Duato and Margot Robbie in the same search result, treat it as a coincidence of attention. The real value lies in understanding each person’s path.
Conclusion
Two careers. Two industries. One search pairing that says more about how people browse than about any real link.
Joaquin Duato spent more than 30 years at Johnson & Johnson and now leads it as chairman and CEO. His 2026 included a major Economic Club interview and a new seat on PepsiCo’s board. His leadership shows up in filings, deals and long-term strategy.
Margot Robbie moved from Australian television to the top of Hollywood. Through LuckyChap, she produced hits like Barbie and a long run of Emerald Fennell films. Her 2026 centered on Wuthering Heights, a film she starred in and produced.
If you remember one point, remember this. Leadership takes many forms. A boardroom and a film set both need vision. They simply reward it in different ways.
Frequently Asked Questions
Are Joaquin Duato and Margot Robbie related or connected?
No. No public record shows any family, business or personal connection between Joaquin Duato and Margot Robbie. They work in separate industries. Their names likely appear together in searches because people compare notable figures.
Is Joaquin Duato still the CEO of Johnson & Johnson in 2026?
Yes. Duato has been CEO since January 2022 and chairman since January 2023. In June 2026 he took part in a public interview at the Economic Club of Washington, D.C. as J&J’s chairman and CEO. In September 2026, PepsiCo announced he’d join its board as an independent director.
What company does Margot Robbie run?
Robbie co-founded LuckyChap Entertainment in 2014 with Tom Ackerley, Josey McNamara and Sophia Kerr. The company produced I, Tonya, Promising Young Woman, Saltburn, Barbie and Wuthering Heights, among other projects.
Did Wuthering Heights come out in 2026?
Yes. Warner Bros. released it in the UK on February 11, 2026 and in the U.S. on February 13, 2026. Robbie stars as Catherine Earnshaw alongside Jacob Elordi, and LuckyChap produced it.
Does Margot Robbie still act after becoming a producer?
Yes. She acts in select projects and produces many more. Recent examples include Barbie in 2023, A Big Bold Beautiful Journey in 2025 and Wuthering Heights in 2026.
What boards does Joaquin Duato serve on besides J&J’s?
PepsiCo announced in September 2026 that Duato will join its 12-member board as an independent director. The seat begins in December.
Quick note for you: The draft runs well over 4,500 words. It uses no outside website as a source and carries no outbound links. Before you publish, check the Oscar nomination list, the acquisition values and the PepsiCo start date against the original announcements. Those are the details readers are most likely to fact-check.
